<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353066</url>
  </required_header>
  <id_info>
    <org_study_id>HCB-UOM-012011</org_study_id>
    <nct_id>NCT01353066</nct_id>
  </id_info>
  <brief_title>Gastric Bypass Versus Best Medical Treatment on Progression of Carotid-intima Media Thickness in Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <acronym>EURDSS</acronym>
  <official_title>Multicenter Randomized Prospective Trial on the Effects of Intensive Medical Treatment of Type 2 Diabetes With and Without Roux-in-Y Gastric Bypass Surgery on Carotid Intima Media Thickness in Grade I Obesity (BMI 30,0-34,9 kg/m2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <brief_summary>
    <textblock>
      Background: Type 2 Diabetes Mellitus (T2DM) is associated with an increased burden for&#xD;
      cardiovascular disease (CVD). Multifactorial interventions are necessary to reduce the CV&#xD;
      risk in T2DM. Bariatric surgery appears to be an alternative for the multifactorial&#xD;
      intervention in T2DM associated with obesity. Data have shown, that clinical trial aiming at&#xD;
      the control of CVRF in T2DM may not translate in the reduction of CV events.&#xD;
&#xD;
      Hypothesis: Intensive medical treatment (IMM) including Roux-en-Y Gastric Bypass (RYGBP)&#xD;
      could be superior in the control of the progression of subclinical atherosclerotic disease,&#xD;
      as evaluated by carotid ultrasound, in subjects with T2DM and a BMI between 30.0 and 34.9&#xD;
      kg/m2.The primary aim of the study is To compare the effects of intensive medical treatment&#xD;
      (IMM) including Roux-en-Y Gastric Bypass (RYGBP) and IMM alone on the progression of the&#xD;
      carotid intima media thickness (CIMT) at 24 months after entry into the trial relative to&#xD;
      baseline.Methodology: Two-year Randomized Clinical Trial, including 240 patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of the progression carotid intima media thickness (CIMT) at 24 months after entry into the trial relative to baseline</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Atherosclerotic Cardiovascular Disease</condition>
  <condition>Subclinical Disease and/or Syndrome</condition>
  <arm_group>
    <arm_group_label>Intensive Medical Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive medical treatment (IMM)+RYGBP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensive Medical Treatment</intervention_name>
    <arm_group_label>Intensive Medical Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IMM+Roux-en-Y Gastric Bypass (RYGBP)</intervention_name>
    <arm_group_label>Intensive medical treatment (IMM)+RYGBP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 35 to 65 years at eligibility visit.&#xD;
&#xD;
          -  Diagnosed with T2DM at least 6 months prior to enrollment, under the active care of a&#xD;
             doctor for at least he six months prior to enrollment, and HbA 1c &gt; 7.0 %.&#xD;
&#xD;
          -  Current treatment for T2DM consisting of multiple doses of insulin with/without&#xD;
             hypoglycemic agents or hypoglycemic agents plus basal insulin.&#xD;
&#xD;
          -  Optimization of diabetes medical treatment prior to inclusion in the study would have&#xD;
             been performed based on best medical practices.&#xD;
&#xD;
          -  Body Mass Index (BMI)&gt; 30.0 kg/m2 and &lt;34.9 kg/m2 at eligibility visit.&#xD;
&#xD;
          -  Willingness to accept random assignment to either treatment group.&#xD;
&#xD;
          -  Expect to live or work within approximately one hour's traveling time from the study&#xD;
             clinic for the duration of the two-year trial.&#xD;
&#xD;
          -  Willingness to comply with the follow-up protocol and successful completion of the&#xD;
             run-in.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiovascular event (myocardial infarction, acute coronary syndrome, coronary artery&#xD;
             angioplasty or bypass, stroke) in the past six months.&#xD;
&#xD;
          -  Current evidence of congestive heart failure (grade II or IV), angina pectoris,&#xD;
             symptomatic peripheral vascular disease or advanced cardiovascular disease.&#xD;
&#xD;
          -  History of severe hypoglycemic episodes associated with medical treatment of type 2 DM&#xD;
&#xD;
          -  Cardiac stress test indicating that surgery would not be safe&#xD;
&#xD;
          -  Pulmonary embolus or thrombophlebitis in the past six months.&#xD;
&#xD;
          -  Cancer of any kind (except basal cell skin cancer or cancer in situ) unless documented&#xD;
             to be disease-free for five years.&#xD;
&#xD;
          -  Significant anemia or history of coagulopathy.&#xD;
&#xD;
          -  Serum creatinine &gt;1.5 mg/dl.&#xD;
&#xD;
          -  Serum total bilirubin or alkaline phosphatase greater than the upper limit of normal,&#xD;
             or ALT greater than twice the upper limit of normal.&#xD;
&#xD;
          -  History of previous surgery contraindicating gastric bypass at the criteria of the&#xD;
             surgical team.&#xD;
&#xD;
          -  Gastric or duodenal ulcer in the past six months.&#xD;
&#xD;
          -  History of intra-abdominal sepsis (except for uncomplicated appendicitis or&#xD;
             diverticulitis more than six months prior to enrollment).&#xD;
&#xD;
          -  Previous organ transplantation.&#xD;
&#xD;
          -  Self-reported HIV-positive status, active tuberculosis, active malaria, chronic&#xD;
             hepatitis B or C, cirrhosis, or inflammatory bowel disease.&#xD;
&#xD;
          -  Currently pregnant or nursing, or planning to become pregnant in the next two years.&#xD;
&#xD;
          -  History of alcohol or drug dependency (excluding caffeine and nicotine) in the past&#xD;
             five years&#xD;
&#xD;
          -  Active psychosocial or psychiatric problem that is likely to interferer with adherence&#xD;
             to the protocol.&#xD;
&#xD;
          -  Score of 17 or higher on the CES-D (depression scale).&#xD;
&#xD;
          -  Current participation in a conflicting research protocol.&#xD;
&#xD;
          -  Presence of any chronic or debilitating disease that would make adherence to the&#xD;
             protocol difficult.&#xD;
&#xD;
          -  12-lead EKG indicating that surgery or intensive medical treatment would not be safe.&#xD;
&#xD;
          -  Diagnosed with diabetes more than 15 years ago.&#xD;
&#xD;
          -  Positive GAD antibodies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Antonio M Lacy, MD</last_name>
    <phone>+34932279854</phone>
    <email>steres@clinic.ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <investigator>
      <last_name>Josep Vidal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>May 11, 2011</study_first_submitted>
  <study_first_submitted_qc>May 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2011</study_first_posted>
  <last_update_submitted>May 11, 2011</last_update_submitted>
  <last_update_submitted_qc>May 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Antonio M Lacy</name_title>
    <organization>Hospital Clínic de Barcelona</organization>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>BMI 30.0-34.9 kg/m2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

